BACKGROUND: Whether guideline-oriented pharmacotherapy prevents the decline in pulmonary function or reduces systemic inflammation associated with chronic obstructive pulmonary disease (COPD) is uncertain. OBJECTIVES: The aim of this study was to assess the outcome of COPD in clinical practice under real-world conditions in Taiwan as measured by pulmonary function and systemic inflammation parameters (C-reactive protein (CRP) or white blood cell (WBC)) after initiation of guideline-oriented pharmacotherapy. METHODS: Newly diagnosed COPD patients were enrolled and prospectively observed in real-world outpatient practice following initiation of pharmacotherapy of COPD. Pulmonary function, WBC and neutrophil counts, and CRP level of COPD patients were assessed annually. This study enrolled 566 patients and 263 returned for follow-up visits. RESULTS: Significantly higher postbronchodilator FVC, FEV1, and FEV1/FVC but lower DLCO were found at 1 year compared to baseline values. During 4-year follow-up period, FVC and FEV1 remained stable. DLCO progressively declined compared to baseline. No significant changes were seen in CRP and neutrophil count over a 3-year period. Values of CRP, WBC, and neutrophil count correlated inversely with FEV1, FVC, FEV1/FVC, and DLCO. CONCLUSIONS: Guideline-oriented pharmacotherapy of COPD improves airflow limitation but does not prevent the alveolar destruction and systemic inflammation under real-world conditions in Taiwan.
BACKGROUND: Whether guideline-oriented pharmacotherapy prevents the decline in pulmonary function or reduces systemic inflammation associated with chronic obstructive pulmonary disease (COPD) is uncertain. OBJECTIVES: The aim of this study was to assess the outcome of COPD in clinical practice under real-world conditions in Taiwan as measured by pulmonary function and systemic inflammation parameters (C-reactive protein (CRP) or white blood cell (WBC)) after initiation of guideline-oriented pharmacotherapy. METHODS: Newly diagnosed COPDpatients were enrolled and prospectively observed in real-world outpatient practice following initiation of pharmacotherapy of COPD. Pulmonary function, WBC and neutrophil counts, and CRP level of COPDpatients were assessed annually. This study enrolled 566 patients and 263 returned for follow-up visits. RESULTS: Significantly higher postbronchodilator FVC, FEV1, and FEV1/FVC but lower DLCO were found at 1 year compared to baseline values. During 4-year follow-up period, FVC and FEV1 remained stable. DLCO progressively declined compared to baseline. No significant changes were seen in CRP and neutrophil count over a 3-year period. Values of CRP, WBC, and neutrophil count correlated inversely with FEV1, FVC, FEV1/FVC, and DLCO. CONCLUSIONS: Guideline-oriented pharmacotherapy of COPD improves airflow limitation but does not prevent the alveolar destruction and systemic inflammation under real-world conditions in Taiwan.
Authors: J P de Torres; E Cordoba-Lanus; C López-Aguilar; M Muros de Fuentes; A Montejo de Garcini; A Aguirre-Jaime; B R Celli; C Casanova Journal: Eur Respir J Date: 2006-02-02 Impact factor: 16.671
Authors: Leslie A Lange; Christopher S Carlson; Lucia A Hindorff; Ethan M Lange; Jeremy Walston; J Peter Durda; Mary Cushman; Joshua C Bis; Donglin Zeng; Danyu Lin; Lewis H Kuller; Deborah A Nickerson; Bruce M Psaty; Russell P Tracy; Alexander P Reiner Journal: JAMA Date: 2006-12-13 Impact factor: 56.272
Authors: Donald P Tashkin; Bartolome Celli; Stephen Senn; Deborah Burkhart; Steven Kesten; Shailendra Menjoge; Marc Decramer Journal: N Engl J Med Date: 2008-10-05 Impact factor: 91.245
Authors: Robert E Walter; Jemma B Wilk; Martin G Larson; Ramachandran S Vasan; John F Keaney; Izabella Lipinska; George T O'Connor; Emelia J Benjamin Journal: Chest Date: 2007-10-01 Impact factor: 9.410
Authors: Don D Sin; S F Paul Man; Darcy D Marciniuk; Gordon Ford; Mark FitzGerald; Eric Wong; Ernest York; Rajesh R Mainra; Warren Ramesh; Lyle S Melenka; Eric Wilde; Robert L Cowie; Dave Williams; Wen Q Gan; Roxanne Rousseau Journal: Am J Respir Crit Care Med Date: 2008-02-28 Impact factor: 21.405
Authors: Ka Pang Chan; Fanny Ws Ko; Hok Sum Chan; Mo Lin Wong; Thomas Yw Mok; Kah Lin Choo; David Sc Hui Journal: Int J Chron Obstruct Pulmon Dis Date: 2017-11-28
Authors: Giuseppe Antonio Palmiotti; Donato Lacedonia; Vito Liotino; Pietro Schino; Francesco Satriano; Pier Luigi Di Napoli; Eugenio Sabato; Vincenzo Mastrosimone; Alfredo Scoditti; Mauro Carone; Elio Costantino; Emanuela Resta; Ettore Attolini; Maria Pia Foschino Barbaro Journal: Int J Chron Obstruct Pulmon Dis Date: 2018-08-15